Key result
Xinli Formula added to standard HF care is linked to ~2% greater 1-week LVEF improvement.
Why the study?
The study was conducted to evaluate the efficacy of Xinli Formula in improving cardiac function, symptoms, and quality of life in patients with heart failure using a hospital database.
Does the addition of Xinli Formula to guideline-directed medical therapy improve cardiac function, exercise tolerance, and biomarkers in patients with heart failure?
Cohort (n=210)
No
Does the addition of Xinli Formula to guideline-directed medical therapy improve cardiac function, exercise tolerance, and biomarkers in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Xinli Formula in HF; leaves open confirmation in prospective RCTs before any practice change.
Objective: To evaluate the efficacy of the "Xinli Formula" in improving cardiac function, symptoms, and quality of life in patients with heart failure using a hospital database. Methods: A retrospective study included 210 patients (2017-2022) divided into Xinli Formula group (n = 107) and non-Xinli Formula group (n = 103). Outcomes included cardiac function parameters, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, 6-min walk distance (6MWD), quality of life (Minnesota Living with Heart Failure Questionnaire, MLHFQ), and inflammatory markers. Data were analyzed using SPSS 26.0. Results: The Xinli Formula group showed significant improvements in Left Ventricular Ejection Fractions (LVEF) (38% → 42%), Left Ventricular End-Systolic Diameter (LVESD) (45 mm → 40 mm), Left Ventricular End-Diastolic Diameter (LVEDD) (60 mm → 55 mm), and 6MWD (350 m → 400 m). MLHFQ scores decreased from 45 to 30. Inflammatory markers and NT-proBNP levels also improved significantly. Conclusion: The Xinli Formula significantly improves cardiac function, exercise tolerance, and quality of life in patients with heart failure and may be an effective adjunctive therapy. Further studies are needed.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2025) conducted a cohort in Heart failure (n=210). Xinli Formula vs. Guideline-directed standard treatment was evaluated on Change in Left Ventricular Ejection Fraction (LVEF) (MD 2.1%, 95% CI 0.9-3.3, p=0.001). In patients with heart failure, the addition of Xinli Formula to standard care significantly improved left ventricular ejection fraction by an additional 2.1% compared to standard care alone over a 1-week period.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: